Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma
Ujjawal H Gandhi, William Senapedis, Erkan Baloglu, Thaddeus J Unger, Ajai Chari, Dan Vogl, Robert F Cornell, Ujjawal H Gandhi, William Senapedis, Erkan Baloglu, Thaddeus J Unger, Ajai Chari, Dan Vogl, Robert F Cornell
Abstract
Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse is common. Current therapeutic strategies include combination and sequential treatments with corticosteroids, alkylating agents, proteasomal inhibitors, immunomodulators, and monoclonal antibodies. These drugs prolong survival but ultimately become ineffective. Exportin 1 (XPO1), a nuclear export protein, is overexpressed in MM cells, and knockdown studies have suggested that XPO1 is essential for MM cell survival. Selective inhibitor of nuclear export (SINE) compounds are novel, orally bioavailable class of agents that specifically inhibit XPO1. Selinexor (KPT-330) is the first-in-human SINE compound. Early phase clinical trials have established the safety profile of this agent and have shown promising efficacy in combination with low-dose dexamethasone and other anti-MM agents. The combination of selinexor and dexamethasone has demonstrated activity in "penta-refractory" MM, (ie, MM refractory to the 5 most active anti-MM agents currently used in treatment). We have reviewed the available data on the molecular implications of XPO1 inhibition in MM. We also reviewed the pertinent early phase clinical data with SINE compounds and discuss management strategies for common toxicities encountered with use of selinexor.
Keywords: Multiple myeloma; SINE compound; Selinexor; Thrombocytopenia; XPO1.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed